FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2941575002> ?p ?o ?g. }

• W2941575002 abstract "Background and Aims: News strategies for the accurate assessment of the state of immunosuppression (IS) in liver transplant recipients are needed to prevent rejection and minimize drug-related side effects. miRNAs can potentially be used as diagnostic or prognostic biomarkers in transplant patients. This study evaluated the capacity of a plasmatic miRNA panel (miR-155-5p, miR-122-5p, miR-181a-5p, and miR148-3p) as an early non-invasive prognostic and diagnostic biomarker for T cell-mediated acute rejection (TCMAR) and subclinical rejection (SCR) in adult liver recipients. Methods: A total of 145 liver recipients were included. All patients received a calcineurin inhibitor with or without mycophenolate mofetil and methylprednisolone. Plasmatic miRNA expression was assessed by qPCR before and at different time-points after liver transplantation. Results: Seventeen patients experienced TCMAR, and eight were diagnosed with SCR during the protocol biopsy at the 3rd month post-transplantation. Pre-transplantation, miR-155-5p expression was significantly higher in TCMAR patients and in SCR patients than in non-rejectors, and miR-181a-5p expression was also significantly higher in SCR patients than in non-rejectors. Post-transplantation, before transaminase-level modification, significantly increased miR-181a-5p, miR-155-5p, and miR-122-5p expression was observed in TCMAR and SCR patients. Binary logistic regression analyses showed, post-transplantation, that TCMAR risk was better predicted by individual expression of miR-181a-5p (LOGIT = -6.35 + 3.87*miR-181a-5p), and SCR risk was better predicted by the combination of miR-181a-5p and miR-155-5p expression (LOGIT = -5.18 + 2.27*miR-181a-5p+1.74*miR-155-5p). Conclusions: Pre-transplantation plasmatic miR-155-5p expression may be useful for stratifying low-immunologic-risk patients, and post-transplantation miR-181a-5p and miR-155-5p may be candidates for inclusion in early, non-invasive prognostic biomarker panels to prevent TCMAR or SCR and better identify patient candidates for IS minimization. Large prospective randomized multicenter trials are needed to refine the cut-off values and algorithms and validate the clinical usefulness of these biomarkers." @default.
• W2941575002 created "2019-05-03" @default.
• W2941575002 creator A5011312501 @default.
• W2941575002 creator A5025512540 @default.
• W2941575002 creator A5029489758 @default.
• W2941575002 creator A5032069891 @default.
• W2941575002 creator A5051787304 @default.
• W2941575002 creator A5053285240 @default.
• W2941575002 creator A5061846529 @default.
• W2941575002 creator A5064417786 @default.
• W2941575002 creator A5067373711 @default.
• W2941575002 creator A5074874245 @default.
• W2941575002 date "2019-04-24" @default.
• W2941575002 modified "2023-10-16" @default.
• W2941575002 title "Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in de novo Adult Liver Transplant Recipients" @default.
• W2941575002 cites W1596457615 @default.
• W2941575002 cites W1691255546 @default.
• W2941575002 cites W1917915070 @default.
• W2941575002 cites W1934677161 @default.
• W2941575002 cites W1968156832 @default.
• W2941575002 cites W1973852067 @default.
• W2941575002 cites W1979601962 @default.
• W2941575002 cites W1994002700 @default.
• W2941575002 cites W1997746871 @default.
• W2941575002 cites W2014869583 @default.
• W2941575002 cites W2025567420 @default.
• W2941575002 cites W2058734479 @default.
• W2941575002 cites W2066112065 @default.
• W2941575002 cites W2072252245 @default.
• W2941575002 cites W2074398100 @default.
• W2941575002 cites W2079145939 @default.
• W2941575002 cites W2085432571 @default.
• W2941575002 cites W2091576301 @default.
• W2941575002 cites W2145646761 @default.
• W2941575002 cites W2152257387 @default.
• W2941575002 cites W2152575748 @default.
• W2941575002 cites W2163721979 @default.
• W2941575002 cites W2258061406 @default.
• W2941575002 cites W2310955554 @default.
• W2941575002 cites W2473391423 @default.
• W2941575002 cites W2487165176 @default.
• W2941575002 cites W2498119267 @default.
• W2941575002 cites W2513682679 @default.
• W2941575002 cites W2521365511 @default.
• W2941575002 cites W2752363848 @default.
• W2941575002 cites W2763130889 @default.
• W2941575002 cites W2765219439 @default.
• W2941575002 cites W2793376808 @default.
• W2941575002 cites W2802957100 @default.
• W2941575002 cites W2862412298 @default.
• W2941575002 cites W2888442197 @default.
• W2941575002 cites W2971005662 @default.
• W2941575002 cites W3025075911 @default.
• W2941575002 doi "https://doi.org/10.3389/fimmu.2019.00873" @default.
• W2941575002 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6491707" @default.
• W2941575002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31068943" @default.
• W2941575002 hasPublicationYear "2019" @default.
• W2941575002 type Work @default.
• W2941575002 sameAs 2941575002 @default.
• W2941575002 citedByCount "19" @default.
• W2941575002 countsByYear W29415750022020 @default.
• W2941575002 countsByYear W29415750022021 @default.
• W2941575002 countsByYear W29415750022022 @default.
• W2941575002 countsByYear W29415750022023 @default.
• W2941575002 crossrefType "journal-article" @default.
• W2941575002 hasAuthorship W2941575002A5011312501 @default.
• W2941575002 hasAuthorship W2941575002A5025512540 @default.
• W2941575002 hasAuthorship W2941575002A5029489758 @default.
• W2941575002 hasAuthorship W2941575002A5032069891 @default.
• W2941575002 hasAuthorship W2941575002A5051787304 @default.
• W2941575002 hasAuthorship W2941575002A5053285240 @default.
• W2941575002 hasAuthorship W2941575002A5061846529 @default.
• W2941575002 hasAuthorship W2941575002A5064417786 @default.
• W2941575002 hasAuthorship W2941575002A5067373711 @default.
• W2941575002 hasAuthorship W2941575002A5074874245 @default.
• W2941575002 hasBestOaLocation W29415750021 @default.
• W2941575002 hasConcept C113280763 @default.
• W2941575002 hasConcept C126322002 @default.
• W2941575002 hasConcept C128057223 @default.
• W2941575002 hasConcept C143998085 @default.
• W2941575002 hasConcept C203014093 @default.
• W2941575002 hasConcept C2779609443 @default.
• W2941575002 hasConcept C2780252810 @default.
• W2941575002 hasConcept C2781197716 @default.
• W2941575002 hasConcept C2911091166 @default.
• W2941575002 hasConcept C55493867 @default.
• W2941575002 hasConcept C71924100 @default.
• W2941575002 hasConcept C86803240 @default.
• W2941575002 hasConcept C90924648 @default.
• W2941575002 hasConceptScore W2941575002C113280763 @default.
• W2941575002 hasConceptScore W2941575002C126322002 @default.
• W2941575002 hasConceptScore W2941575002C128057223 @default.
• W2941575002 hasConceptScore W2941575002C143998085 @default.
• W2941575002 hasConceptScore W2941575002C203014093 @default.
• W2941575002 hasConceptScore W2941575002C2779609443 @default.
• W2941575002 hasConceptScore W2941575002C2780252810 @default.
• W2941575002 hasConceptScore W2941575002C2781197716 @default.
• W2941575002 hasConceptScore W2941575002C2911091166 @default.
• W2941575002 hasConceptScore W2941575002C55493867 @default.
• W2941575002 hasConceptScore W2941575002C71924100 @default.

• next